目的 探讨同步放化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法 选取我院2014年收治的晚期NSCLC患者102例,随机分为观察组和对照组,对照组以紫杉醇联合顺铂化疗方案(TP)化疗治疗,观察组加用三维适形放疗同步放化疗治疗,观察两组的临床疗效和不良反应。结果 观察组和对照组患者的总有效率分别为43.14%和21.57% (P<0.05),两组患者的总控制率分别为84.31%和66.67% (P<0.05)。两组患者Ⅲ～Ⅳ级胃肠道反应、白细胞减少、骨髓抑制的发生率差异无统计学意义(P>0.05),观察组比对照组增加了放射性肺炎和放射性食管炎的发生 (P<0.05)。两组患者生活质量比较,差异具有统计学意义(P＜0.05)。结论 同步放化疗治疗晚期NSCLC可以显著提高治疗的总有效率、肿瘤的控制率及生活质量,但也使不良反应增加,选择治疗方案时应根据个体情况综合考虑。

Objective To study the clinical efficacy of concurrent chemoradiotherapy in the treatment of advanced non small cell lung cancer (NSCLC). Methods 102 cases of advanced NSCLC treated in our hospital in 2014 were selected and randomly divided into the observation group and the control group. Patients in control group were treated by chemotherapy with Paclitaxel combined Cisplatin (TP), while those in observation group were treated by concurrent chemoradiotherapy with three- dimensional conformal radiotherapy and TP. The clinical efficacy and adverse reactions of the two groups were observed. Results The total effective rate of the observation group and the control group were 43.14% and 21.57% (P<0.05), respectively. The total control rate of the two groups were 84.31% and 66.67%(P<0.05). In two groups III ~ IV gastrointestinal tract reaction, leukopenia, bone marrow suppression occurrence had no statistical significance(P>0.05). Incidence of radiation pneumonitis and radiation esophagitis increased in observation group(P<0.05). The difference of quality of life between the two groups was statistically significant(P<0.05). Conclusion Concurrent radiotherapy and chemotherapy in the treatment ofadvanced non-small cell lung cancer(NSCLC)can not only significantly improve the treatment, tumor control rate and quality of life, but also make adverse reaction increased. Treatment options should be chosen based on individual circumstances into account

目的 探讨传统支气管针吸活检 (cTBNA )与超声支气管镜引导下针吸活检(EBUS-TBNA)对于肺部疾病伴有肺门及纵膈淋巴结肿大患者的诊断价值。方法 2012 年8月—2014年6月对在我院行CT检查提示肺部伴有肺门和/或纵膈淋巴结病变的患者38例, 分别利用cTBNA或EBUS-TBNA检查对肿大的淋巴结行TBNA,对所获得的标本进行相应的细胞学检查。结果 38例病例均经组织病理学诊断后确诊,并经过6个月的随访,其中cTBNA组(n=19)经组织病理明确诊断的包括:1例结核,5例小细胞肺癌,6例腺癌,3例鳞癌,1例大细胞癌,3例慢性炎症,cTBNA细胞学诊断阳性诊断率为63.16%(12/19),cTBNA组细胞学诊断肺癌的敏感度为66.67％(10/15),特异度为100％。EBUS-TBNA组(n=19)组织病理学诊断明确的1例为肺结核,1例为纵隔恶性肿瘤,1例为结节病,1例大细胞癌,1例小细胞癌,7例腺癌,5例鳞癌,2例为慢性炎症,EBUS-TBNA细胞学阳性诊断率为78.94%(15/19)。两种方法在诊断肺门及纵膈淋巴结肿大的疾病中有差异(P<0.05)。EBUS-TBNA组细胞学诊断肺癌的敏感度为86.67％(13/15),特异度为100％。结论 EBUS-TBNA细胞学检查对肺部疾病伴有肺门及纵膈淋巴结肿大的诊断率较cTBNA高,可明显提高检查阳性率,具有重要临床意义。

Objective To evaluate the value of clinical application between cTBNA and EBUS-TBNA in diagnosis of mediastinal and hilar lymph nodes. Methods Between August 2012 and June 2014, 38 in-patients with mediastinal and hilar lymph nodes took conventional transbronchial needle aspiration( cTBNA,n=19) or endobronchial ultrasound-guided transbronchial needle aspiration(EBUS-TBNA, n=19), and we were comparing the diagnostic results of two methods. Results 19 patients in the cTBNA group were diagnosed by forceps biopsy,including 1 case of lung cancer and 162 cases of tuberculosis, 5 cases of small cell lung cancer, 6 cases of adenocarcinoma, 3 cases of squamous cell carcinoma, 1 case of large cell carcinoma, 3 cases of chronic inflammation, a cytological diagnosis of TBNA positive in 12 cases (63.16%). In the EBUS-TBNA group (n=19), the patients were diagnosed by accepting forceps biopsy, 1 case of tuberculosis, 1 case of mediastinal malignant tumor, 1 cases of sarcoidosis, 1 cases of large cell carcinoma, 1 case of small cell carcinoma, 7 cases of adenocarcinoma, 5 cases of squamous cell carcinoma, 2 cases of chronic inflammation, EBUS-TBNA cytology positive rate of diagnosis was 14 (73.68%). Two techniques in the diagnosis of mediastinal and hilar lymph nodes have statistically significant(P<0.05). The sensitinty of cytology in the diagnosis of lung caner was 86.67%(13/15),and the specificity was 100%(EBUS-TBNA). Conclusion EBUS-TBNA is an effective tool in the diagnosis of mediastinal and hilar lymph nodes and superior to cTBNA.

目的 探讨两种不同治疗方案治疗老年糖尿病合并初治涂阳肺结核患者的临床疗效。方法 将85例老年糖尿病合并初治涂阳肺结核患者分为每日疗法组(n=43)和间歇疗法组(n=42)。比较两组2、3、6个月及疗程结束痰菌转阴率、胸片吸收情况、并发症发生率。结果 两组治疗2个月痰菌转阴率每日疗程组高于间歇疗法组,但两组间无差异,但5、6个月末及疗程结束转阴率每日疗法均高于间歇疗法(P<0.05);治疗后每日疗程组病灶总吸收率(97.62%)高于间歇疗法组(79.07%),且差异有统计学意义(P<0.05);治疗过程中两组出现不良反应情况相比较差异无统计学意义(P>0.05)。结论 使用每日疗法并适当延长强化期及巩固期疗程治疗老年糖尿病合并初治涂阳肺结核的痰菌转阴率及病灶吸收率均优于间歇疗法,且安全性两者无差异,值得临床借鉴。

目的 了解非结核分枝杆菌肺病患者营养风险、营养不足发生率,以及营养支持的应用状况,为临床实施营养干预提供参考依据。方法 对2012年10月—2014年10月在广州市胸科医院就诊的非结核分枝杆菌肺病患者(符合NRS2002评定标准)的营养风险筛查与营养支持状况进行回顾性分析。结果 402例患者中,营养不足和营养风险的发生率分别为35.8％(144/402)和66.7％(268/402);所有患者中,总体营养支持率为60.0%(241/402), 使用肠外营养与肠内营养的比例为3.2∶1;老年患者,女性患者,复治患者更是发生营养风险和营养不足的高危人群;存在营养风险患者的营养支持率为82.1%(220/268),不存在营养风险患者营养支持率为15.7%(21/134)。结论 非结核分枝杆菌肺病患者存在较高比例的营养不足和营养风险,肠外肠内营养临床应用存在不合理性;应推广和使用NRS2002营养评定方法和肠内肠外营养指南,作为实施营养支持的依据。

Objective To investigate prevalence of nutritional risk, undernutrition, and nutritional support of hospitalized patients with non-tuberculosis mycobacteria. Methods Adult patients in Guangzhou Chest Hospital from October 2012 to October 2014 were enrolled by fix-point consecutive sampling. Nutritional Risk Screening 2002 (NRS2002) was performed and nutritional support was evaluated in all patients. Results A total of 402 patients were enrolled.Overall prevalence of undernutrition was 35.8%, and nutritional risk was 66.7%. Among all the patients, the rate of nutritional support was 60.0%, including 82.1%of patients with nutritional risk and 15.7% of non-risk patients. Gerontal patients, retreatment patients and female patients are in the greater possibility of being expose to nutritional risk or undernutrition. Conclusion A large proportion of inpatients with non-tuberculosis mycobacteria were at nutritional risk or undernutrition.The application of parenteral or enteral nutritional support currently maybe inappropriate. NRS2002 and parenteral or enteral nutrition guideline are required to affording nutritional support.

目的 探讨罗伊适应模式对肺癌患者术后生活质量的影响。方法 将2012年3月—2015年7月来我院就诊的178例肺癌术后患者,随机分为试验组85例和对照组93例;对照组患者按护理常规进行护理,试验组在常规护理基础上给予罗伊适应模式护理干预;出院时分别比较两组患者住院适应性、治疗依从性、病人满意度及患者生活质量评分。结果 试验组住院适应率为87.1%(74例),对照组住院适应率为66.7%(62例),两组差异有显著性(P<0.01);试验组治疗依从性优良率为88.2%(75例)、对照组治疗依从性优良率72.0%(67例),两组差异有显著性(P<0.01);试验组患者满意度为89.4%(76例),高于对照组患者满意度73.1%(68例),两组差异有显著性(P<0.01);试验组生活质量评分,总体健康得分(74.1±8.3)高于对照组(56.7±5.9),且差异有统计学意义(P<0.01)。结论 罗伊适应模式护理干预,可以提高肺癌患者手术后的住院适应性、治疗依从性及病人满意度,显著改善患者生活质量,在临床推广罗伊适应模式护理干预具有现实意义。

Objective To investigate　the effect of Roy adaptation model on quality of life in patients for lung cancer after surgery. Methods 178 cases of　patients with lung cancer after surgery operation　were randomly divided into observation groups(85 cases) and control groups(93 cases). The control group was treated with routine nursing care and the observation group was treated on the basis of routine nursing care plus Roy adaptation model nursing interventions. When the two groups were compared in patients hospitalized and discharged adaptability, treatment compliance, patient satisfaction and patient quality of life score. Results Hospitalization adaptation in the observation group was 87.1%(74 cases) and control group was 66.7%(67 cases). There was statistically significant difference between two groups(P<0.01); Excellent treatment compliance of observation group was 88.2%(75 cases) and control group was 72.0%(67 cases). There was statistically significant difference between two groups(P<0.01); the observation group patient satisfaction were 89.4%(76 cases), it was higher than 73.1%(68 cases) of control group. There was statistically significant difference between two groups(P<0.01); quality of life in general health score(74.1±8.3) in the observation group was higher than that of control group(56.7±5.9),and there was statistically significant difference between two groups(P<0.01). Conclusion Roy adaptation model nursing intervention may improve the adaptability hospitalized the patients with lung cancer after surgery, treatment compliance and the patient satisfaction, and significantly improve the quality of life of patients. It is worthy of promotion clinically.

目的 探讨心理健康干预对复治肺结核患者在整个治疗过程中生活质量影响,为加强结核病的宣教奠定坚实的基础。方法 选取广州市结核病防治所在治的复治肺结核病人72例,随机分成宣教组和普通组,选取2名有丰富经验的主管护师,经专业心理师培训指导,护长考核,负责宣教组的工作,而普通组则由轮班护士进行,无作特别要求。对比两组心理健康干预前后的变化。结果 两组症状自评量表(SCL-90)测评相比较,宣教组优于普通组,差异有统计学意义(P<0.05)。宣教组的生理健康总评及精神健康总评比对照组好,差异均有统计学意义(P<0.05)。结论 通过对门诊复治结核病患者进行心理健康干预,能有效改变复治病人的心理和生理健康,提高生活质量。

目的 回顾分析慢性阻塞性肺疾病急性加重期并或不并肺部结核感染在感染及营养方面指标的差异性,明确结核感染对AECOPD的影响。方法 选取2013年7月—2015年6月因急性发作入住我院的COPD患者105例,根据GOLD 2011对COPD的诊断标准及卫生部2008年制定的肺结核诊断标准将其分为无结核组、稳定期组、好转期组及进展期四组。分别在入院时测定患者白细胞计数、中性粒细胞比率、总淋巴细胞计数、淋巴细胞比值、红细胞沉降率、血红蛋白浓度、血清白蛋白及C反应蛋白及体重指数。结果 各组感染指标比较,WBC、CRP两指标差异不显著(P>0.05),而无结核组相较于其他三组,NEUT%更高(F=4.004,P=0.010)、LY%及ESR更低(F/P分别为3.668/0.015和20.197/0.000);各组营养指标比较,合并有肺结核的三组,其Hb、ALB及BMI均比无结核组低,达到统计学差异(P<0.05),而TLC在各组间无差异(F=0.858,P=0.466)。结论 合并有结核感染的AECOPD患者更容易出血贫血(Hb降低)、低蛋白血症(ALB降低)、低体重(BMI降低)、中性粒细胞含量偏低(NEUT%降低)而血沉(ESR)、淋巴细胞比率(LY%)升高的情况,对出现此类情况的AECOPD患者应进行结核感染相关检查。

目的 比较榄香稀和顺铂胸腔灌注治疗肺癌恶性胸腔积液的疗效。方法 肺癌合并恶性胸腔积液患者56例,榄香稀组29例:胸腔内注射榄香烯400 mg+地塞米松10 mg+2%普鲁卡因10 mL;顺铂组27例:顺铂80 mg+地塞米松10 mg。每周1次,治疗4周。同时记录不良反应。结果 56例均可评价疗效,榄香稀组完全缓解11例,部分缓解14例,有效率86.2%。顺铂组完全缓解6例,部分缓解10例,有效率59.3%,差异有统计学意义,榄香稀组生活质量较顺铂组改善。结论 榄香稀治疗恶性胸腔积液疗效好,可提高生活质量,毒副反应小。

目的 评价阿奇霉素序贯疗法治疗小儿支原体肺炎的临床疗效及药物经济学效果。方法 将我院儿科于2011年3月—2013年8月收治的522例支原体肺炎患儿随机分为静滴组(n=265)和序贯组(n=287),两组均给予阿奇霉素进行疗程为5 d的治疗,静滴组采用静脉滴注的给药方法进行治疗,序贯组采用静脉滴注2 d后口服序贯给药3 d的方法进行治疗,运用药物经济学原理对两种给药方案进行成本－效果分析。结果 静滴组和序贯组的总有效率分别为94.0%(249/265)和92.7%(266/287),两组比较差异无统计学意义(P>0.05),但静滴组的成本高于序贯组(P<0.01);静滴组和序贯组的不良反应发生率分别为34.7%(92/265)和26.9%(76/287),两组比较差异有统计学意义(P<0.05)。结论 采用序贯疗法治疗小儿支原体肺炎符合安全、有效、经济的临床用药原则,值得临床广泛推荐。

Objective To evaluate the clinical efficacy and pharmacoeconomic effect of sequential therapy of azithroycin on treatment of community mycoplasmal pneumonia(MP)in chindren. Methods 522 cases with MP from March 2011 to August 2013 in pediatrics department of our hospital were randomly divided into intravenous-drip group(n=265)and sequential-therapy group(n=287),and both two groups were treated by azithromycin for 5 days.The intravenous-drip group was treated with intravenous drip of azithromycin,and the sequential-therapy group was treated with azithromycin in the way of intravenous drip for 2 days and oral-taken for 3 days.The two treatments were cost-effectiveness analyzed by pharmacoeconomic theory. Results The total efficiency of the sequential-therapy group and intravenous-drip group were 94.0%(249/265)and 92.7%(266/287),respectively.There was no different between the sequential-therapy group and the intravenous-drip group(P<0.05).But the cost in intravenous-drip group was higher than that in sequential-therapy group(P<0.01).The incidence of adverse reaction of the sequential-therapy group and intravenous-drip group were 94.0% 34.7%(92/265)and 26.9%(76/287),respectively.And it was significant different between the two groups(P<0.05). Conclusions The treatment of sequential therapy of azithromycin is safety,effective and economical.And it is worthy to be widely recommended in clinical.

目的 调查盐酸氨溴索对放射性肺损伤中转化生长因子β1(TGF-β1)以及肿瘤坏死因子α(TNF-a)水平的影响。方法 选取共98例在放射治疗局部晚期肺癌患者,随机分为治疗组和对照组。自放疗开始予治疗组中患者盐酸氨溴索口服,剂量60 mg,每天三次,持续应用3个月。然后对两组患者血浆中TGF-β1和TNF-α的水平进行分析。临床症状和病情变化情况采用高分辨率计算机断层扫描进行检测。结果 对照组中TGF-β1水平显著升高(11.8±5.5 ng/mL),而在盐酸氨溴索治疗组中,增加不显著(5.5±2.6 ng/mL,P＜0.001)。同样,对照组中TNF-α的水平也较治疗组中升高,(对照组:5.1±1.3,治疗组:2.6±0.8 ng/mL,P＜0.001)。结论 盐酸氨溴索能有效降低放疗后血浆TGF-β1及TNF-α水平,降低早期出现的放射性肺炎和晚期出现的肺纤维化发生机率,提高治疗效果及患者生活质量。

Objective The aim is to investigate the effect of ambroxol on radiation lung injury and the expression of transforming growth factor β1(TGF-β1),and tumor necrosis factor α(TNF-α)in plasma. Methods Ninety-eight patients with locally advanced lung cancer in radiotherapy were randomized into treatment and control groups.Patients in the treatment group took ambroxol orally at a dosage of 60 mg,three times per day for 3 months from the beginning of radiotherapy.The expression of TGF-β1 and TNF-αin plasma was analyzed.The clinical symptoms and lung diffusing capacity were monitored using high resolving power computed tomography. Results The level of TGF-β1 in the control group was increased(11.8 ± 5.5 ng/mL),whereas in ambroxol-treated patients,the increase was not significant(5.5 ± 2.6 ng/mL,P＜0.001). Radiotherapy-induced elevation of TNF-α levels,seen in control patients,was also abolished after treatment with ambroxol(5.1 ± 1.3 vs 2.6 ± 0.8 ng/mL,P＜0.001). Conclusion Ambroxol can obviously decrease the plasma TGF-β1 and TNF-α levels after radiotherapy,and decrease the chances of early radiation pneumonitis and late pulmonary fibrosis,and improve treatment effect and quality of life of patients.